| hormone replacement therapy | In females, treatment with sex hormones for a number for reasons, including menopause, partial or full hysterectomy, or amenorrhoea.In women, treatment with sex hormones is indicated for a number of reasons, including menopause, partial or full hysterectomy, or amenorrhoea. After menopause, conjugated oestrogens, estradiol, or estrone sulfate are given to reduce pain during intercourse, limit blood vessel effects, and prevent loss of bone mass. After radical hysterectomy, conjugated oestrogens are given for similar reasons. After menopause or partial hysterectomy, progestin is administered at the same time to offset an increased risk of endometrial cancer. In some amenorrhoeas, oestrogen is given to restore menses; if the therapy is unsuccessful, this may indicate the presence of pathology, for instance, pituitary tumour. Benefits for postmenopausal women include a lowered risk of heart attack (oestrogen lowers LDL and raises HDL levels), and prevention of osteoporosis, since the rate of bone loss is directly linked to a drop in oestrogen levels (see perimenopause). Medical opinion about the hazard posed by such therapy remains divided. Some studies have indicated increased incidence of breast cancer; however, a comprehensive 1992 review of the literature contradicted this finding. (05 Mar 2000) |
|---|---|
| renal replacement therapy | Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the kidneys. (12 Dec 1998) |
| replacement therapy | Therapy designed to compensate for a lack or deficiency arising from inadequate nutrition, from certain dysfunctions (e.g., glandular hyposecretion), or from losses (e.g., haemorrhage); replacement may be physiological or may entail administration of a substitute (e.g., a synthetic oestrogen in place of estradiol). (05 Mar 2000) |
| oestrogen replacement therapy | <endocrinology, gynaecology> The use of oestrogenic substances in postmenopausal or other oestrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, dyspareunia, and progressive development of osteoporosis. (12 Dec 1998) |
| enzyme replacement therapy | A type of medical treatment for patients who lack an important enzyme, the missing enzyme is injected into the patient. (09 Oct 1997) |
| receptors, pituitary hormone-regulating hormone | Cell surface receptors that bind the hypothalamic hormones regulating pituitary cell differentiation, proliferation, and hormone synthesis and release, including the pituitary-releasing and release-inhibiting hormones. The pituitary hormone-regulating hormones are also released by cells other than hypothalamic neurons, and their receptors also occur on non-pituitary cells, especially brain neurons, where their role is less well understood. Receptors for dopamine, which is a prolactin release-inhibiting hormone as well as a common neurotransmitter, are not included here. (12 Dec 1998) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| hormones, hormone substitutes, and hormone antagonists | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. (12 Dec 1998) |
| hormone therapy | Treatment which results in the raising or lowering of hormone levels. Changes in levels can effect some breast cancers, those that need hormones for growth. (16 Dec 1997) |
| follicle-stimulating hormone-releasing hormone | A decapeptide of hypothalamic origin capable of accelerating pituitary secretion of follitropin. Synonym: follicle-stimulating hormone-releasing factor, follicle-stimulating hormone-releasing hormone. Origin: follicle-stimulating hormone + L. Libero, to free, + -in (05 Mar 2000) |
| luteinizing hormone/follicle-stimulating hormone-releasing factor | gonadotrophin-releasing hormone |
| luteinizing hormone-releasing hormone | A hormone that controls sex hormones in men and women. Also called lhrh. (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |